From: A novel microRNA signature for the detection of melanoma by liquid biopsy
Melanoma patients | Normal controls | |
---|---|---|
(N=16) | (N=22) | |
Gender | ||
Male | 14 (12,5%)a | 10 (45,5%)a |
Female | 2 (87,5%) a | 12 (54,5%) a |
Age (range) | ||
Male | 58 (27-82) b | 44 (21-67) b |
Female | 54 (50-59) b | 48,5 (22-75) b |
BRAF status | ||
Mutated | 5 (31,3%) a | – |
Wild-type | 11 (68,7%) a | |
M stage | ||
M0 | 2 (12,5%) a | |
M1a | 8 (50%) a | – |
M1b | 1 (6,3%) a | |
M1c | 5 (31,2%) a | |
LDH | ||
≤ULN | 14 (87,5%) a | – |
>ULN | 2 (12,5%) a | |
Prior lines of therapy | ||
0 | 16 (100%) a | – |
1 | 0 |